

# Khalad Maliyar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8281716/publications.pdf>

Version: 2024-02-01

25  
papers

161  
citations

1478505

6  
h-index

1281871

11  
g-index

25  
all docs

25  
docs citations

25  
times ranked

205  
citing authors

#	ARTICLE	IF	CITATIONS
1	Biologic Use in Pediatric Patients With Hidradenitis Suppurativa: A Systematic Review. Journal of Cutaneous Medicine and Surgery, 2022, 26, 176-180.	1.2	5
2	Lichenoid Drug Eruptions Associated With the Use of Biologic Therapy: A Systematic Review. Journal of Cutaneous Medicine and Surgery, 2022, 26, 521-522.	1.2	1
3	Development of granuloma annulare in patients on biologic therapies: A systematic review. Journal of the American Academy of Dermatology, 2021, 85, 1594-1597.	1.2	0
4	Hair pull test: A clinical update for patients with Asian- and Afro-textured hair. Journal of the American Academy of Dermatology, 2021, 85, 1599-1601.	1.2	2
5	Development of morphea in patients receiving biologic therapies: A systematic review. Journal of the American Academy of Dermatology, 2021, 84, 1081-1085.	1.2	3
6	Drugs associated with development of pityriasis rubra pilaris: A systematic review. Journal of the American Academy of Dermatology, 2021, 84, 1071-1081.	1.2	7
7	Treatment outcomes in confluent and reticulated papillomatosis: A systematic review. Journal of the American Academy of Dermatology, 2021, 84, 825-829.	1.2	5
8	Alopecia Areata Related Paradoxical Reactions in Patients on Dupilumab Therapy: A Systematic Review. Journal of Cutaneous Medicine and Surgery, 2021, 25, 451-452.	1.2	9
9	A Systematic Review of Efficacy and Safety of Monotherapy and Combination Therapy With Biologic for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Journal of Cutaneous Medicine and Surgery, 2021, 25, 598-615.	1.2	6
10	Squamous cell carcinoma arising within discoid lupus erythematosus lesions: A systematic review. JAAD International, 2021, 2, 1-4.	2.2	4
11	Biologic treatment in pediatric Stevens-Johnson syndrome/toxic epidermal necrolysis: A systematic review. Journal of the American Academy of Dermatology, 2021, 85, 1011-1013.	1.2	4
12	Development of dermatomyositis in patients on biologic therapy: A systematic review. Journal of the American Academy of Dermatology, 2021, , .	1.2	0
13	Hereditary haemorrhagic telangiectasia: A case report. SAGE Open Medical Case Reports, 2021, 9, 2050313X2110030.	0.3	1
14	A systematic review of eczematous eruptions in patients receiving biologic therapy. Journal of the American Academy of Dermatology, 2021, 85, 1630-1635.	1.2	5
15	Full Body Skin Examination Practices Among Canadian Dermatologists: Results of a Nationwide Survey. Journal of Cutaneous Medicine and Surgery, 2021, 25, 212-215.	1.2	1
16	Stevens Johnson Syndrome and Toxic Epidermal Necrolysis Reactions to BRAF and MEK Inhibitors in Patients with Melanoma: A Systematic Review. Journal of the American Academy of Dermatology, 2020, 85, 981-983.	1.2	2
17	Reply to: "Skin damage among health care workers managing coronavirus disease 2019". Journal of the American Academy of Dermatology, 2020, 83, e169-e170.	1.2	10
18	Modifications to dermatology residency education during the COVID-19 pandemic. Journal of the American Academy of Dermatology, 2020, 83, e235-e236.	1.2	15

#	ARTICLE	IF	CITATIONS
19	Long-Term Single Center Experience in Treating Plaque Psoriasis With Guselkumab. Journal of Cutaneous Medicine and Surgery, 2020, 24, 588-595.	1.2	29
20	Guselkumab dosing interval optimization in adult patients with psoriasis: A retrospective, multicenter case series. Journal of the American Academy of Dermatology, 2020, 83, 1813-1814.	1.2	5
21	Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment. Journal of the American Academy of Dermatology, 2020, 83, 579-586.	1.2	30
22	A Brief History of Psoriasis Management in Canada. Journal of Cutaneous Medicine and Surgery, 2020, 24, 273-277.	1.2	1
23	COVID-19 and wound care: A Canadian perspective. JAAD International, 2020, 1, 79-80.	2.2	2
24	Risankizumab, an IL-23p19 Inhibitor for Psoriasis: A Review of the Current Literature. Skin Therapy Letter, 2020, 25, 1-4.	0.3	0
25	Genital Ulcer Disease: A Review of Pathogenesis and Clinical Features. Journal of Cutaneous Medicine and Surgery, 2019, 23, 624-634.	1.2	14